Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. April 2023 04:39 ET | Quelle: Genmab A/S

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second...
20. April 2023 19:45 ET | Quelle: Genmab A/S

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc....
18. April 2023 06:25 ET | Quelle: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
17. April 2023 02:00 ET | Quelle: Genmab A/S

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody...
06. April 2023 16:33 ET | Quelle: Genmab A/S

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; April 6, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
03. April 2023 16:30 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
03. April 2023 10:12 ET | Quelle: Genmab A/S

Completion of share buy-back program

Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023, Genmab...
29. März 2023 16:19 ET | Quelle: Genmab A/S

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
29. März 2023 16:10 ET | Quelle: Genmab A/S

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to...
29. März 2023 09:54 ET | Quelle: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management...

Vorherige Seite

Nächste Seite